Efficacy of recombinant human growth hormone in the treatment of dwarfism in children at different ages and its effect on bone metabolism, insulin-like growth factor-1 and vitamin D3 / 中国基层医药

ABSTRACT

Objective:To investigate the effects of recombinant human growth hormone on bone metabolism, insulin-like growth factor-1 (IGF-1) and vitamin D3 in dwarfism children at different ages.Methods:Sixty children with dwarfism who received treatment in Shaoxing Women's and Children's Health Care Hospital from January 2018 to January 2019 were included in this study. They were divided into group A (age at 4-9 years, n = 32) and group B (age at >9-13 years, n = 28) according to different ages. Two groups of children were treated with recombinant human growth hormone for 6 months. Total effective rate in two groups was recorded. Before and after treatment, bone metabolism index, serum IGF-1 and 25-hydroxyvitamin D3 levels were measured in each group. Results:Total effective rate in the group A was significantly higher than that in the group B [90.62% (29/32) vs. 67.85% (19/28), χ2 = 4.838, P < 0.05]. Before treatment, there were no significant differences in serum levels of calcium, phosphorus, zinc, IGF-1 and 25 hydroxyvitamin D3 between groups A and B (all P > 0.05). After treatment, serum levels of calcium, phosphorus, zinc, IGF-1 and 25 hydroxyvitamin D3 in the group A were (1.99 ± 0.53) mmol/L, (1.76 ± 0.14 ) mmol/L, (88.97 ± 6.89) μmol/L, (325.57 ± 15.29) ng/L, (89.47 ± 15.58) ng/L, respectively,which were significantly higher than those in the group B [(1.71 ± 0.55) mmol/L, (1.65 ± 0.15) mmol/L, (85.22 ± 6.76) μmol/L, (312.29 ± 13.88) ng/L, (80.11 ± 15.31) ng/L, t = 2.005, 2.936, 2.121, 3.502, 2.340, all P < 0.05]. Conclusion:Recombinant human growth hormone has better curative effect on dwarfism in children at 4-9 years old than in children at 9-13 years old, and it can effectively improve bone metabolism, IGF-1, vitamin D3 and other indicators.